Louis Menand on Psychiatry

Episode Summary

Executive Summary: Russ Roberts and Louis Menand examine whether psychiatry can be a science, focusing on depression, antidepressants, the DSM, and the influence of placebo effects, Freud’s legacy, and pharmaceutical incentives. They conclude psychiatry can help, but its knowledge is limited, outcomes are often black-boxed, and cultural, ethical, and economic forces strongly shape diagnosis and treatment.

Main Topics: What is depression? (Priority: 5/5): The conversation starts with the basic diagnostic problem: distinguishing clinical depression from normal sadness caused by life events. Menand argues the line is often empirically blurry, though severe endogenous cases clearly exist. Treatment effectiveness and the 'dodo bird' effect (Priority: 5/5): They discuss research comparing psychotherapy, cognitive behavioral therapy, medication, and placebos. Menand notes many treatments perform similarly on average, suggesting broad efficacy but limited precision in matching treatments to patients. Placebo effects and antidepressants (Priority: 5/5): The discussion centers on Irving Kirsch’s claim that antidepressants often work mainly through placebo effects, as well as criticisms of that claim and evidence that severe depression may respond better to medication than placebo. Freud, psychoanalysis, and the rise of biological psychiatry (Priority: 4/5): Menand explains how psychoanalysis dominated mid-century psychiatry, then was displaced by drug-based, biologically framed approaches. The DSM shifted away from Freudian assumptions by 1980. Money, insurance, and the expansion of diagnoses (Priority: 5/5): They examine how pharmaceutical profits, insurance reimbursement rules, and legal incentives can encourage diagnostic inflation and a broader medicalization of mood and behavior problems. Risks, side effects, and addiction (Priority: 4/5): The conversation addresses claims that some antidepressants may increase suicidality in younger patients and that older anxiolytics like Valium and Librium were addictive, raising concerns about unintended harms. Authenticity, grief, and limits of science (Priority: 4/5): They close with a philosophical discussion of whether one would take a hypothetical grief pill or use drugs to alter personality. Menand argues some life experiences, including grief, are tied to authenticity and may not be appropriate targets for medical intervention.

Key Arguments: Many psychiatric symptoms are real and impairing even when their causes are ambiguous or not clearly biological. Psychiatric treatments often help only at the margin; there is no universal panacea and outcomes are frequently modest. The overlap in outcomes across therapies suggests common factors such as empathy, expectation, and patient belief matter greatly. Kirsch’s placebo-centered account is provocative but likely too sweeping to explain all antidepressant benefits. The DSM’s diagnostic categories are deeply shaped by institutional needs, especially insurance reimbursement and legal defensibility. Freud’s influence declined not because his language was disproven in a simple way, but because psychiatry moved toward biologically grounded explanations and treatments. Scientific framing does not eliminate black boxes; even modern psychopharmacology lacks a full explanation of how antidepressants work. Some psychiatric medications may carry serious risks, including addiction and possibly increased suicidality, which complicates claims of straightforward benefit. Questions about grief, creativity, and personality change are partly moral and cultural, not merely scientific. Patients and families are often vulnerable to expert authority, especially when insurance and social pressure make medication seem like the default option.

Data Points: DSM first edition: 1952 - Menand notes the DSM has been criticized since its creation in 1952. DSM second edition: 1968 - He describes early DSM editions as still influenced by Freud. DSM third edition: 1980 - By 1980, Freud was largely removed from psychiatric classification. Antidepressant response rate: 50–60% - Roberts and Menand discuss the approximate effectiveness range of psychiatric treatments. Anxiolytic era: 1950s–1960s - Miltown, Equinal, Librium, and Valium were highlighted as blockbuster mood/anxiety drugs from this period. Prozac licensing: 1987 or 1988 - Menand references the long-running debate over suicidality and SSRIs since Prozac’s approval. Meta-analysis sample size: about 700 patients - He critiques a JAMA meta-analysis of antidepressants for using a relatively small sample. Number of antidepressants on market: about 25 - Menand says the JAMA study looked only at Paxil, not the broader class. DSM-5 timing: "in a couple years" from 2010 - He notes the DSM-5 was expected to remove the grief exception to depression diagnosis.

Pivotal Quotes: "the problem is that it's impossible to distinguish empirically sadness over some life event... and what you're calling clinical depression" — Louis Menand: On the difficulty of separating normal sadness from medical depression. "pretty much everybody comes out about the same" — Louis Menand: Describing the 'dodo bird effect' across psychiatric treatments. "science doesn't have all the answers either" — Louis Menand: On the limits of psychiatry and medicine as explanatory systems.

Implications: The episode suggests psychiatry can relieve suffering, but diagnosis and treatment are shaped by uncertainty, incentives, and values. Listeners should be cautious about assuming drug-based answers are definitive or purely scientific.